Log in

Krystal Biotech Stock Forecast, Price & News

+2.24 (+4.84 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $48.49
50-Day Range
MA: $43.97
52-Week Range
Now: $48.49
Volume597,096 shs
Average Volume166,880 shs
Market Capitalization$953.51 million
P/E RatioN/A
Dividend YieldN/A
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Read More
Krystal Biotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:KRYS



Sales & Book Value

Annual SalesN/A
Book Value$11.72 per share


Net Income$-19,090,000.00


Market Cap$953.51 million
Next Earnings Date11/2/2020 (Estimated)
OptionableNot Optionable
+2.24 (+4.84 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

How has Krystal Biotech's stock price been impacted by Coronavirus?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KRYS shares have decreased by 2.9% and is now trading at $48.49.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Krystal Biotech?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Krystal Biotech

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Krystal Biotech

How were Krystal Biotech's earnings last quarter?

Krystal Biotech Inc (NASDAQ:KRYS) issued its earnings results on Monday, August, 10th. The company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.45) by $0.08.
View Krystal Biotech's earnings history

What price target have analysts set for KRYS?

8 analysts have issued 12 month price targets for Krystal Biotech's stock. Their forecasts range from $60.00 to $115.00. On average, they anticipate Krystal Biotech's share price to reach $85.67 in the next twelve months. This suggests a possible upside of 76.7% from the stock's current price.
View analysts' price targets for Krystal Biotech

Who are some of Krystal Biotech's key competitors?

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV) and Vaxart (VXRT).

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:
  • Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 54)
  • Ms. Suma M. Krishnan, Founder, COO & Director (Age 54)
  • Ms. Pooja Agarwal, VP of Product Devel. (Age 40)
  • Mr. Antony A. Riley, Chief Financial Officer (Age 51)
  • Ms. Gloria Lin, Accounting Mang.

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (6.76%), Vanguard Group Inc. (3.69%), Point72 Asset Management L.P. (2.74%), First Light Asset Management LLC (2.36%), Goldman Sachs Group Inc. (1.64%) and Victory Capital Management Inc. (1.60%). Company insiders that own Krystal Biotech stock include Daniel Janney, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends for Krystal Biotech

Which institutional investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Nicholas Investment Partners LP, Verition Fund Management LLC, Atom Investors LP, Blair William & Co. IL, Alps Advisors Inc., Bank of New York Mellon Corp, Chartwell Investment Partners LLC, and Bank of America Corp DE. Company insiders that have sold Krystal Biotech company stock in the last year include Krish S Krishnan, and Suma Krishnan.
View insider buying and selling activity for Krystal Biotech

Which institutional investors are buying Krystal Biotech stock?

KRYS stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., First Light Asset Management LLC, Victory Capital Management Inc., Goldman Sachs Group Inc., FMR LLC, Artal Group S.A., Handelsbanken Fonder AB, and Vanguard Group Inc..
View insider buying and selling activity for Krystal Biotech

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $48.49.

How big of a company is Krystal Biotech?

Krystal Biotech has a market capitalization of $953.51 million. The company earns $-19,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Krystal Biotech employs 37 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.